Amikacin therapy for serious gram-negative infection

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Severe Gram-negative bacterial infections pose significant treatment challenges, especially when resistant to conventional antibiotics.
• Gentamicin resistance in Gram-negative bacilli necessitates alternative therapeutic options.
• Amikacin sulfate is an aminoglycoside antibiotic with broad-spectrum activity.

Purpose of the Study:

• To evaluate the efficacy and safety of amikacin sulfate in treating severe Gram-negative infections.
• To assess drug levels in various body fluids.
• To identify adverse effects associated with amikacin sulfate treatment.

Main Methods:

• A prospective study involving 18 patients with 19 severe infections.
• Amikacin sulfate administered at a dose of 15 mg/kg/day.
• Monitoring of bacteriologic cure, serum, bile, and pleural fluid drug levels, and adverse events.

Main Results:

• Bacteriologic cure was achieved in 18 out of 19 infections (94.7%).
• Effective drug concentrations were demonstrated in serum, bile, and pleural fluid.
• Adverse events included drug-related fever (1 patient), rash with monilial intertrigo (1 patient), and reversible renal toxicity (3 patients). No ototoxicity was observed.

Conclusions:

• Amikacin sulfate is an effective antibiotic for treating severe Gram-negative infections, particularly those caused by gentamicin-resistant organisms.
• The drug is well-tolerated, with manageable and reversible side effects.
• Therapeutic drug monitoring confirmed adequate drug levels in key body fluids.